Latest Articles
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia - 2 Minute Medicine
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia 2 Minute Medicine
Published: Feb. 17, 2026, 12:15 a.m.
George L. Maxwell, MD, discusses phase 3 SUNFLOWER trial to evaluate Mirena for nonatypical endometrial hyperplasia - Contemporary OB/GYN
George L. Maxwell, MD, discusses phase 3 SUNFLOWER trial to evaluate Mirena for nonatypical endometrial hyperplasia Contemporary OB/GYN
Published: Dec. 12, 2025, 2:26 p.m.
Bayer Aims To Broaden Mirena’s Use With Phase III Endometrial Hyperplasia Study - Citeline News & Insights
Bayer Aims To Broaden Mirena’s Use With Phase III Endometrial Hyperplasia Study Citeline News & Insights
Published: Dec. 4, 2025, 11:19 a.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - BioSpace
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia BioSpace
Published: Dec. 3, 2025, 2:11 p.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - sharewise.com
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia sharewise.com
Published: Dec. 3, 2025, 5:04 a.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Business Wire
Published: Dec. 2, 2025, 1:05 p.m.
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia - Stock Titan
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia Stock Titan
Published: Dec. 2, 2025, 1:05 p.m.
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer
Published: Dec. 2, 2025, 7:30 a.m.
Link copied to clipboard!